MTHFR Deficiency: What Is This Gene Mutation?

MTHFR is a gene that provides instructions for making an enzyme called methylenetetrahydrofolate reductase, and variants in this gene are among the most common genetic polymorphisms in humans. When people talk about an “MTHFR mutation,” they almost always mean one of two well-studied single-letter changes in the DNA code, known as C677T and A1298C, that reduce how well the enzyme works. These are not rare mutations in the traditional sense. Depending on your ancestry, anywhere from about 10 to 60 percent of people carry at least one copy of the C677T variant, which makes framing it as a “deficiency” misleading for most carriers. The real story is more layered than the wellness internet suggests.

What the MTHFR Enzyme Actually Does

The MTHFR enzyme sits at a critical junction in your body’s folate cycle. Its job is to convert one form of folate (5,10-methylenetetrahydrofolate) into another form (5-methyltetrahydrofolate), which your body then uses to recycle the amino acid homocysteine back into methionine.¹ Methionine is needed to make S-adenosylmethionine, the molecule your cells use for methylation, a chemical tagging process that helps regulate gene activity, build neurotransmitters, and process toxins. When MTHFR works poorly, less 5-methyltetrahydrofolate gets made, homocysteine can build up in the blood, and the downstream supply of methyl groups may be reduced. That chain of events is why this one enzyme has been linked to such a wide range of health topics.

The Two Common Variants

The C677T variant (sometimes written as Ala222Val) is the more studied of the two. Having two copies of the T version, one inherited from each parent, produces an enzyme that is less stable than normal. The protein has a tendency to lose its helper molecule, a form of riboflavin called FAD, and to fall apart into inactive fragments more easily.² People with two copies (homozygous TT) show enzyme activity reduced by roughly 70 percent compared to the normal version, while those with one copy (heterozygous CT) show about a 35 percent reduction.³ Homozygous carriers tend to have higher blood levels of homocysteine, particularly when their folate intake is low.⁴

The A1298C variant (Glu429Ala) also reduces enzyme activity, though typically to a lesser degree than C677T.⁵ On its own, A1298C does not seem to raise homocysteine levels in any clinically meaningful way. A study of over 1,200 people found that neither the AC nor CC versions of A1298C were associated with significantly higher fasting homocysteine, regardless of folate status.⁶ Some people carry one copy of each variant (compound heterozygous), and there is ongoing debate about whether that combination has meaningful clinical effects beyond what each variant does alone.

How Common These Variants Are Around the World

MTHFR variants are strikingly common, and their frequency varies dramatically by geography and ethnicity. A large meta-analysis estimated a global prevalence of the 677T allele at about 24 percent and the TT genotype at roughly 8 percent, with Europeans having the highest rates (the T allele was found in about 34 percent of European populations) and sub-Saharan Africans having the lowest (around 10 percent).⁷ Among Europeans specifically, southern European populations tend to carry the variant at especially high rates, with frequencies of the T allele reaching above 50 percent in Italian and Spanish groups.⁸

Within a single country, the variation can be just as dramatic. A study of over 15,000 Chinese Han adults found that the TT genotype ranged from about 6 percent in the tropical south (Hainan) to 41 percent in the northern province of Shandong, with a clear increasing gradient from south to north. Interestingly, the A1298C variant showed exactly the opposite pattern, being more common in the south and rarer in the north.⁹ This kind of geographic distribution has led researchers to suspect that the 677T variant may have been maintained at high frequencies by natural selection, possibly because it conferred some survival advantage during fetal development in certain environments.¹⁰

Neural Tube Defects and Pregnancy

The strongest and most consistently replicated health association for MTHFR C677T involves neural tube defects like spina bifida. A meta-analysis pooling 25 studies found that mothers with two copies of the T allele had roughly double the odds of having a child with a neural tube defect compared to mothers with the normal CC genotype.¹¹ That risk was elevated across multiple ethnic groups. The mechanism makes intuitive sense: if the mother’s body is less efficient at processing folate, the developing embryo may not get enough of the active folate it needs during the crucial early weeks when the neural tube is closing.

Recurrent pregnancy loss has also been studied. A meta-analysis of data from over 14,000 subjects found that the A1298C variant was associated with an increased risk of recurrent miscarriage, but this effect was population-specific. It was significant in Caucasian populations but showed no association in East Asian groups.¹² Findings like these are a good reminder that MTHFR effects rarely operate in a vacuum; folate status, other gene variants, and population background all shape what these polymorphisms actually mean for an individual.

The Cardiovascular Connection

Elevated homocysteine has been considered a risk factor for heart disease, and since C677T raises homocysteine, researchers have spent decades trying to determine whether the variant itself increases cardiovascular risk. The evidence is mixed in ways that matter.

One study found that the TT genotype was significantly more common in patients with coronary artery disease than in controls, especially in those with severe multi-vessel disease.¹³ Another study found the TT genotype was much more common in patients with arterial disease who lacked traditional risk factors like high cholesterol, high blood pressure, or diabetes. In those patients, the odds ratio was over 5, meaning TT carriers were about five times more likely to have arterial disease when other common culprits were absent. The same study found a nearly threefold increased odds of venous thrombosis.¹⁴

But a separate study that looked specifically at premature coronary artery disease and restenosis after angioplasty found no significant association with the MTHFR variant, even while acknowledging that high homocysteine itself does raise risk.¹⁵ The picture that emerges is that the variant’s cardiovascular impact seems to depend heavily on context: how much folate you eat, what other risk factors you carry, and possibly your ethnic background. In populations with high folate intake (or in countries that fortify flour with folic acid), the variant may barely move the needle because adequate folate keeps homocysteine in check.

Links to Mental Health

A large meta-analysis of psychiatric studies found that the C677T variant is significantly associated with schizophrenia and major depression in the general population, and with bipolar disorder among TT homozygotes specifically.¹⁶ These are statistical associations across pooled studies, not cause-and-effect proof. The proposed mechanism runs through methylation and neurotransmitter production: if your body makes less methylfolate, it may produce less of the methyl groups needed to synthesize serotonin, dopamine, and norepinephrine. Whether MTHFR status should change how depression is treated remains an active area of investigation rather than settled clinical practice.

MTHFR and Cancer Risk

The relationship between MTHFR and cancer is one of those places where the story gets counterintuitive. You might assume that reduced enzyme activity is always bad, but for colorectal cancer, the TT genotype may actually be protective when folate intake is adequate. A meta-analysis found that people with the TT genotype and high folate intake had about a 32 percent lower risk of colorectal cancer compared to those with the same genotype and low folate intake.¹⁷ An earlier systematic review reached a similar conclusion, finding reduced colorectal cancer risk for the TT genotype under conditions of high total folate.¹⁸

The explanation researchers have proposed is that when MTHFR activity is reduced, more folate stays in the form used for DNA synthesis and repair rather than being diverted to methylation. If enough folate is available overall, this shift might reduce the kind of DNA damage that leads to cancer. However, a more recent large-scale analysis found no significant interaction between the C677T variant and folate intake on colorectal cancer risk, so the protective story is not fully settled.¹⁹

Severe MTHFR Deficiency Is a Different Condition Entirely

It is important to distinguish the common polymorphisms from severe MTHFR deficiency, which is a rare inherited metabolic disorder. Severe deficiency involves private loss-of-function mutations (more than 50 have been identified) that reduce enzyme activity to somewhere between 0 and 20 percent of normal. This leads to dangerously high homocysteine levels, homocystinuria, and progressive neurological deterioration that typically appears in infancy or childhood. It is a life-threatening condition requiring aggressive medical treatment, and it has nothing to do with the common C677T or A1298C variants that affect millions of healthy people. The confusion between the two is one of the biggest misunderstandings in the consumer genetics space.

How MTHFR Status Affects Drug Reactions

One of the more practical reasons to know your MTHFR status involves methotrexate, a drug used in cancer treatment, rheumatoid arthritis, and other conditions. Methotrexate works by blocking folate metabolism, and if your MTHFR enzyme is already working at reduced capacity, the drug can hit harder than expected. A study of osteosarcoma patients treated with high-dose methotrexate found that those with the C677T variant had higher rates of liver toxicity and fever.²⁰ A separate study in children with leukemia found that those carrying the CT or TT genotype had over 6 times the risk of liver damage in a low-risk subgroup and nearly twice the risk of mucosal damage in a high-risk subgroup compared to children with the normal CC genotype.²¹

Another drug interaction worth knowing about involves nitrous oxide, the anesthetic commonly called laughing gas. Nitrous oxide inactivates vitamin B12, which is needed for the same homocysteine-recycling pathway that MTHFR feeds into. In a person with already-reduced MTHFR function, nitrous oxide can push that pathway further into failure. A case report in the New England Journal of Medicine described serious adverse effects in a child with MTHFR deficiency after nitrous oxide exposure.²² While this is more relevant to severe deficiency than to common polymorphism carriers, it is the kind of information worth mentioning to an anesthesiologist if you know your status.

Should You Get Tested?

This is where the gap between consumer genetics culture and clinical medicine is widest. The American College of Medical Genetics and Genomics (ACMG) published a practice guideline stating there is a lack of evidence to support routine MTHFR polymorphism testing.²³ Their reasoning is that the common variants are so prevalent in the population that they do not reliably predict disease in any individual, and that the standard clinical response (ensuring adequate folate intake) applies to everyone regardless of genotype.

Despite that guidance, MTHFR testing has become one of the most popular results people seek from direct-to-consumer DNA kits and third-party raw data interpretation services. A study of people who used these services found that about 62 percent were motivated by individual health implications, and roughly 30 percent shared their results with a medical provider. Responses from those providers ranged from disinterest to, in some cases, diagnosis of genetic conditions. Many participants reported difficulty understanding their results even when they were satisfied with the overall experience.²⁴ The mismatch is real: people feel empowered by the information, but the clinical value for most common variant carriers is genuinely unclear.

Folate Supplementation and the Methylfolate Question

If you do carry MTHFR variants, the most common practical advice you’ll encounter is to take methylfolate (5-MTHF) instead of regular folic acid. The logic is straightforward: standard folic acid needs to be converted through several steps including the MTHFR enzyme before your body can use it, while methylfolate bypasses that bottleneck because it is already in the active form. A review in a European obstetrics journal noted that because 5-MTHF does not require activation, it is immediately available and does not accumulate in the blood the way unconverted folic acid can in people with reduced enzyme function.²⁵

That said, studies comparing the two supplements at equal doses have found that they have comparable bioavailability and are similarly effective at improving blood folate levels and lowering homocysteine in the general population.²⁶ For most people, including many C677T carriers, standard folic acid works fine because the enzyme is reduced in activity, not absent. The case for methylfolate is strongest in TT homozygotes with documented folate metabolism issues or in clinical situations where folic acid accumulation could mask a vitamin B12 deficiency.

MTHFR and DNA Methylation

One reason MTHFR variants generate so much interest in the wellness world is the connection to methylation, a process sometimes marketed as the key to everything from energy levels to detoxification. On a biological level, MTHFR variants in the C677T and A1298C positions have been associated with changes in global DNA methylation patterns in some studies.²⁷ However, a study that directly measured DNA methylation in oral cells across the three C677T genotypes found no significant differences.²⁸ The relationship between carrying an MTHFR variant and having functionally altered methylation across your genome is still unclear, and the sweeping claims made by supplement companies about “methylation support” protocols often go well beyond what the evidence supports.

Methylation is genuinely important. It helps silence genes that should be off, activates genes that should be on, and plays roles in cell division and repair. But the leap from “this enzyme variant slightly reduces one input into the methylation cycle” to “you need a $90-per-month supplement stack to fix your methylation” involves a lot of unsupported assumptions. Your body has backup pathways for regenerating methionine, folate status is modifiable through diet, and the common variants leave plenty of residual enzyme activity in most carriers.

When Your Ancestry Shapes the Risk Profile

Because the frequency of MTHFR variants varies so widely across populations, the health implications are not uniform either. In populations where the variant is very common, like southern Europe or northern China, the average diet and environment may have co-evolved to partially offset the enzyme’s reduced function. Regions with historically folate-rich diets (heavy in leafy greens and legumes) may see less clinical impact from the same genotype that causes problems in populations with lower folate availability. The recurrent pregnancy loss data illustrates this principle clearly: the A1298C variant was a significant risk factor in Caucasian populations but not in East Asian populations, even after controlling for genotype frequency.¹² Similarly, the cardiovascular impact of C677T appears much more pronounced in populations where folate intake is low or where food fortification has not been implemented.

Countries that mandate folic acid fortification of grain products (the United States, Canada, Chile, and others) have effectively blunted the most serious public health consequence of MTHFR variants. Neural tube defect rates dropped significantly after fortification programs began, which benefited everyone but likely helped TT homozygotes the most. In countries without mandatory fortification, carriers of these variants are more dependent on their dietary choices and supplement habits to maintain adequate folate status.